First Report of Cerebral Venous Thrombosis Following Inactivated-Virus Covid Vaccination (Sinopharm and Sinovac)


      Cerebral venous thrombosis (CVT) is an uncommon cerebrovascular disease, which has been reported with covid infection as well as covid vaccines, particularly AstraZeneca and Janssen vaccines. We present four consecutive cases of CVT after receiving either Sinopharm or Sinovac vaccine, both of which are composed of an inactivated-virus. All the patients recovered well with anticoagulation and discharged with a good functional outcome. This is the first case series reporting CVT following the administration of these vaccines.



      AZ (AstraZeneca vaccine), Covid (Coronavirus disease 2019), CVT (Cerebral venous thrombosis), EMA (European Medicine Agency), EUA (Emergency Use Authorization), mRS (modified Rankin scale), SARS-COV-2 (Severe Acute Respiratory Syndrome Cronavirus 2), WHO (World Health Organization)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Johns Hopkins University Coronavirus Resource Center. 14 October 2021; ([Online]Available from)
      2. 7 Vaccines Approved for Use by WHO. 14 October 2021; ([Online] Available from:)
        • Omeish H
        • Najadat A
        • Al-Azzam S
        • et al.
        Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study.
        Hum Vaccin Immunother. 2021; : 1-8
        • ITV News
        AstraZeneca vaccine: timeline of what's happened since European countries suspended use of Covid jab. 14 October 2021; ([Online] Available from:) ([Accessed])
        • US Food and Drug Administration
        FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review. 14 October 2021; ([Online] Available from:)
        • Hameed S
        • Wasay M.
        Covid-19 vaccines and cerebral venous thrombosis.
        Pak J Neurol Sci (PJNS). 2021; 16: 3
        • Krzywicka K
        • Heldner MR
        • Sánchez van Kammen M
        • et al.
        Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
        Eur J Neurol. 2021;
        • Kim JH
        • Marks F
        • Clemens JD.
        Looking beyond COVID-19 vaccine phase 3 trials.
        Nat Med. 2021; 27: 205-211
        • Riad A
        • Sağıroğlu D
        • Üstün B
        • et al.
        Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey.
        J Clin Med. 2021; 10: 2629
        • Saeed BQ
        • Al-Shahrabi R
        • Alhaj SS
        • et al.
        Side effects and perceptions following Sinopharm COVID-19 vaccination.
        Int J Infect Dis. 2021; 111: 219-226
        • Nagaraja D
        • Noone ML
        • Bharatkumar VP
        • Christopher R.
        Homocysteine, folate and vitamin B12 in puerperal cerebral venous thrombosis.
        J Neurol Sci. 2008; 272: 43-47
        • Kalita J
        • Singh VK
        • Misra UK.
        A study of hyperhomocysteinemia in cerebral venous sinus thrombosis.
        Indian J Med Res. 2020; 152: 584-594
        • Hameed S
        • Wasay M
        • Soomro BA
        • et al.
        Cerebral venous thrombosis associated with COVID-19 infection: An observational, multicenter study.
        Cerebrovasc Dis Extra. 2021; 11: 55-60